Associations - temozolomide

No biomarker	Anaplastic Astrocytoma	No biomarker	Anaplastic Astrocytoma	temozolomide Sensitive: A1 - Approval temozolomide Sensitive : A1	temozolomide Sensitive: A1 - Approval temozolomide Sensitive : A1
No biomarker	Glioblastoma	No biomarker	Glioblastoma	temozolomide Sensitive: A1 - Approval temozolomide Sensitive : A1	temozolomide Sensitive: A1 - Approval temozolomide Sensitive : A1
IDH1 mutation	Astrocytoma	IDH1 mutation	Astrocytoma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
MGMT promoter methylation	Glioblastoma	MGMT promoter methylation	Glioblastoma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
No biomarker	Glioma	No biomarker	Glioma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
No biomarker	Sarcoma	No biomarker	Sarcoma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
No biomarker	Uveal Melanoma	No biomarker	Uveal Melanoma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
No biomarker	Cutaneous Melanoma	No biomarker	Cutaneous Melanoma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	temozolomide + capecitabine Sensitive: A2 - Guideline temozolomide + capecitabine Sensitive : A2	temozolomide + capecitabine Sensitive: A2 - Guideline temozolomide + capecitabine Sensitive : A2
No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	temozolomide + irinotecan Sensitive: A2 - Guideline temozolomide + irinotecan Sensitive : A2	temozolomide + irinotecan Sensitive: A2 - Guideline temozolomide + irinotecan Sensitive : A2
No biomarker	Rhabdomyosarcoma	No biomarker	Rhabdomyosarcoma	temozolomide + irinotecan + vincristine Sensitive: A2 - Guideline temozolomide + irinotecan + vincristine Sensitive : A2	temozolomide + irinotecan + vincristine Sensitive: A2 - Guideline temozolomide + irinotecan + vincristine Sensitive : A2
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	temozolomide + irinotecan + vincristine Sensitive: A2 - Guideline temozolomide + irinotecan + vincristine Sensitive : A2	temozolomide + irinotecan + vincristine Sensitive: A2 - Guideline temozolomide + irinotecan + vincristine Sensitive : A2
No biomarker	Ependymoma	No biomarker	Ependymoma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
No biomarker	Lymphoma	No biomarker	Lymphoma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
No biomarker	Medulloblastoma	No biomarker	Medulloblastoma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
No biomarker	Pancreatic Cancer	No biomarker	Pancreatic Cancer	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
IDH2 mutation	Astrocytoma	IDH2 mutation	Astrocytoma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
MGMT promoter methylation	Glioblastoma	MGMT promoter methylation	Glioblastoma	temozolomide + lomustine Sensitive: A2 - Guideline temozolomide + lomustine Sensitive : A2	temozolomide + lomustine Sensitive: A2 - Guideline temozolomide + lomustine Sensitive : A2
MGMT unmethylation	Glioblastoma	MGMT unmethylation	Glioblastoma	temozolomide Sensitive: B - Late Trials temozolomide Sensitive : B	temozolomide Sensitive: B - Late Trials temozolomide Sensitive : B
IDH1 R132H	Anaplastic Astrocytoma	IDH1 R132H	Anaplastic Astrocytoma	temozolomide Sensitive: B - Late Trials temozolomide Sensitive : B	temozolomide Sensitive: B - Late Trials temozolomide Sensitive : B
IDH2 mutation	Glioma	IDH2 mutation	Glioma	temozolomide Sensitive: B - Late Trials temozolomide Sensitive : B	temozolomide Sensitive: B - Late Trials temozolomide Sensitive : B
IDH1 mutation	Glioma	IDH1 mutation	Glioma	temozolomide Sensitive: B - Late Trials temozolomide Sensitive : B	temozolomide Sensitive: B - Late Trials temozolomide Sensitive : B
MGMT promoter methylation	Anaplastic Astrocytoma	MGMT promoter methylation	Anaplastic Astrocytoma	temozolomide Sensitive: B - Late Trials temozolomide Sensitive : B	temozolomide Sensitive: B - Late Trials temozolomide Sensitive : B
MGMT unmethylation	Glioma	MGMT unmethylation	Glioma	temozolomide + interferon α-2b Sensitive: B - Late Trials temozolomide + interferon α-2b Sensitive : B	temozolomide + interferon α-2b Sensitive: B - Late Trials temozolomide + interferon α-2b Sensitive : B
IDH1 mutation	Glioblastoma	IDH1 mutation	Glioblastoma	temozolomide Sensitive: C2 – Inclusion Criteria temozolomide Sensitive : C2	temozolomide Sensitive: C2 – Inclusion Criteria temozolomide Sensitive : C2
MGMT promoter methylation	Ewing Sarcoma	MGMT promoter methylation	Ewing Sarcoma	temozolomide + irinotecan Sensitive: C2 – Inclusion Criteria temozolomide + irinotecan Sensitive : C2	temozolomide + irinotecan Sensitive: C2 – Inclusion Criteria temozolomide + irinotecan Sensitive : C2
miR-30b-3p underexpression	Glioblastoma	miR-30b-3p underexpression	Glioblastoma	temozolomide Sensitive: C3 – Early Trials temozolomide Sensitive : C3	temozolomide Sensitive: C3 – Early Trials temozolomide Sensitive : C3

temozolomide

Associations
(114)

Associations
(114)

temozolomide

Associations(114)

Associations(114)

Associations
(114)

Associations
(114)